NAPERVILLE, Ill., Oct. 18, 2017 /PRNewswire/ -- Pharmazz, Inc. has received exclusive license to U.S. patent for treatment
Chronic pain affects over 100 million Americans annually, and inadequate control of pain costs the nation an estimated $560-$635 billion annually in direct care and loss of productivity. Inadequate analgesia can increase the body's stress response and suppress cellular immunity and increase chances of postsurgical infections. Acute postoperative pain can manifest into chronic persistent postsurgical pain if not managed adequately. The annual costs of medications prescribed for nonmalignant chronic pain totaled $17.8 billion annually in 2010. Of these, opioids were among the top categories, at an annual cost of $3.6 billion.
About Pharmazz, Inc. Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.
Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.
ContactPharmazz, Inc. Shruti Gulati[email protected]
View original content:http://www.prnewswire.com/news-releases/pharmazz-inc-has-received-exclusive-license-to-us-patent-for-treatment-of-opioid-tolerance-and-pain-management-300539223.html
SOURCE Pharmazz, Inc.
Subscribe to our Free Newsletters!
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...View All